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Mature cystic teratomas (MCT) in the ovary rarely undergo malignant transformation. Moreover, adenocarcinoma
of the gastrointestinal type is much rarer. We present two cases of perimenopausal female pateints with mature
cystic teratoma of single ovary, while local adenocarcinoma arising in the MCT. The malignancies showed
immunohistochemical features of intestinal differentiation, such as strong positivity for CDX-2, villin and CK-20, and
negativity for CK-7. Furthermore, the mutation analysis of molecular alteration revealed a KRAS gene mutation in
the intestinal adenocarcinoma part, extending into benign intestinal-type epithelium linings. Yet the mutation was
not present in the epidermal component of the teratoma. We present these as two unique cases of mucinous
adenocarcinoma of the intestinal type arising from mature cystic teratoma. Moreover, we also submit that this KRAS
mutation might contribute to identify malignant transformation of a MCT and suggest possible effect on targeted
treatment decisions for anti-epidermal growth factor receptor (EGFR) therapy in metastasized patients.
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The most common tumor of ovary is mature cystic tera-
toma (MCT), which arises from germ cells and accounts
for more than 20% of all ovarian tumors [1]. Malignant
transformation of MCTs occurs in 1-2% of all these tu-
mors [2]. During the malignancies arising in the MCT,
squamous cell carcinoma is the most common type [3],
with adenocarcinomas comprising only 6.8% of the ma-
lignant changes [4,5]. Furthermore, adenocarcinomas of the
gastrointestinal type are much less frequent. So far there
have been few reports of adenocarcinoma of the gastro-
intestinal type in the ovary arising from an MCT [6-8].
We present two cases with similarity of primary adeno-
carcinoma of the gastrointestinal type likely arising in a
mature cystic teratoma of the ovary. Either patient had no
evidence of a primary tumor elsewhere by previous
medical history or radiographic survey. After extensive
histological examination, the cyst with adenocarcinoma* Correspondence: niexiuyishi@126.com
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unless otherwise stated.was found in continuity with a benign cystic lesion, which
seemed at first slightly thicker compared to the surround-
ing normal wall. Yet, the microscopic evaluation revealed
this part of cyst covered by epithelium showing malignant
transformation into carcinoma with clearly defined irregu-
lar glands infiltrating into the stroma. The immunohisto-
chemical (IHC) staining of the malignant change showed
strong positivity for cytokeratin-20 (CK-20), villin and
caudal type homeobox transcription factor 2 (CDX-2),
while negative for CK-7. Moreover, as a number of studies
had proved Kirsten rat sarcoma viral oncogene homolog
(KRAS) and v-Raf murine sarcoma viral oncogene homo-
log B1 (BRAF) oncogene mutations are recognized bio-
markers that predict lack of response to anti-epidermal
growth factor receptor (EGFR) antibody therapies and are
associated with a worse prognosis in patients with meta-
static adenocarcinoma in colorectal cancer [9-11]. To in-
vestigate further treatment in case of recurrence and
metastasis of intestinal carcinoma for those two patients,
we evaluate molecular alteration on oncogene mutation in
cysts carrying adenocarcinoma, which showed positive for
KRAS mutation and the mutation was extended into the
benign intestinal-type epithelium of the cyst.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tinal type was likely arising from a mature cystic tera-
toma. We also submit that this KRAS mutation might
be helpful in identifying malignant transformation of a
MCT and suggest possible effect on targeted treatment
decisions for anti-epidermal growth factor receptor
(EGFR) therapy in metastasized patients.
Case presentation
The first patient was a 51-year-old perimenopausal fe-
male, gravida 3, para 1, who was admitted with occa-
sional nausea, abdominal pain and bloating for the past
few years. Her previous medical, surgical, gynecological,
and family histories were all unremarkable, with regular
menstrual cycle. A mass in the left adnexal region was
found in a routine pelvic examination. Ultrasound scan
revealed the presence of an approximately 6 cm complex
cystic mass of the left ovary. And there were no abnormal
findings of the uterus and right adnexae. The patient had
slightly elevated serum level of only one tumor marker. Her
carbohydrate atigen 19–9 (CA199) was elevated to 41.9
U/ml (normal < 35 U/ml), while the other serum tumor
markers, including carcinoembrionic antigen (CEA), CA
125, α-fetoprotein(AFP), were all within the normal ranges.
An exploratory laparoscopy with frozen section of the
left ovarian tumor was performed. After the result of
frozen section confirming malignant change in MCT,
the procedure was changed to a total hysterosalpingo-
oophorectomy with 400 mg intraperitoneal carboplatin.
Appendectomy and omentectomy were also carried out.
Postoperatively, the patient opted for adjuvant chemo-
therapy, consisting of 6 cycles of paclitaxel (135 mg/m2)
and carboplatin (area under the curve [AUC] of 5). After
adjuvant chemotherapy, the patient’s CA199 went back
to normal and a whole-body positron emission tomo-
graphic scan was performed, the result of which was
negative. The patient remains free of disease 13 months
following diagnosis.Figure 1 The microscopic examination of the left ovarian mass. A, C
B, Malignant glandular epithelium was arising in continuity with benign muco
infiltration in the stroma (haematoxylin - eosin, magnification x20); D, Magnified m
magnification x 100); E, Magnified intestinal-type adenocarcinoma in the stromMacroscopically, the left ovary contained a smooth
cystic mass (5.8 cm × 4.5 cm) filling with sebaceous ma-
terial, hair and teeth. The wall was average 0.1 cm -
0.3 cm thin. Most of the inner surface of the mass was
smooth, and had partial thicking-like nodules lining a
rough surface. The right ovary was 3.2 cm × 1.2 cm ×
1.0 cm and otherwise unremarkable. The cervix con-
tained 1 small mucous cyst, and the uterus contained 2
small leiomyomas (0.8 cm – 1.0 cm diameter).
The microscopic examination of the left ovarian mass
revealed components of a classic mature teratoma
(Figure 1A). Most inner surface of the cyst was covered by
squamous epithelium while malignant glandular epithelium
(Figure 1B and D) was arising in continuity with benign
mucous epithelium. The tumor was clearly defined ir-
regular glands with stroma invasion (Figure 1C and E).
Tumour cells showed IHC-positivity of CDX-2 (Figure 2A),
CK-20 (Figure 2B), villin (Figure 2C). Moreover, the IHC
analysis showed negativity of CK-7 (Figure 2D), oestrogen
receptor (ER) and human epidermal growth factor 2
(HER2) (data not shown) in the adenocarcinoma part.
Genetic mutation was detected in various components
of the tumor mass, including malignant adenocarcin-
oma, benign intestinal-type epithelium and the squa-
mous epithelium of the mature cystic teratoma. EGFR
inhibition-targeted therapy is a new biologic therapy for
the treatment of metastatic colorectal cancer which is
also adenocarcinoma of intestinal type [9,10]. KRAS was
an oncogene whose mutation status is a prognostic fac-
tor for survival rate and predictive of response to EGFR
inhibition-targeted therapy in intestinal adenocarcinoma
[10-13]. BRAF [14,15] and EGFR (epidermal growth fac-
tor receptor) [16] genes, which are important co-factors
of KRAS gene in the EGFR signaling pathway in the car-
cinogenesis, invasion and metastasis of colorectal cancers,
also have prognostic value for patients with metastasis of
adenocarcinoma. So we chose KRAS, BRAF and EGFR as
targets of mutation detection. Interestingly, quantitativelassic mature teratoma (haematoxylin - eosin, magnification x200);
us epithelium (haematoxylin - eosin, magnification x20); C, Tumour
alignant glandular epithelium of B from the same field (haematoxylin - eosin,
a of C from the same field (haematoxylin - eosin, magnification x 100).
Figure 2 Immunohistchemical staining of the adenocarcinoma part arising from an ovarian teratoma. The adenocarcinoma part showed
positive on CDX-2 (A), CK-20 (B) and villin (C) while CK-7 (D) was negative (magnification x 400).
Figure 3 Mutation analysis revealed a KRAS mutation not only in the adenocarcinoma part but also benign intestinal-type epithelium
linings. A, A mutation was found in codon 12 of the KRAS gene (NM_004985.3):c. 35G > T, p. (Gly12Val) in malignant glandular epithelium; B and
C, There was no mutation in BRAF or EGFR genes in malignant glandular epithelium; D, The same mutation was found in benign intestinal-type
epithelium in the same patient.
Li et al. Journal of Ovarian Research 2014, 7:85 Page 3 of 6
http://www.ovarianresearch.com/content/7/1/85
Li et al. Journal of Ovarian Research 2014, 7:85 Page 4 of 6
http://www.ovarianresearch.com/content/7/1/85polymerase chain reaction (qPCR) revealed a mutation
in codon 12 of the KRAS gene (NM_004985.3):c. 35G >
T, p. (Gly12Val) in both the intestinal adenocarcinoma
(Figure 3A) and benign intestinal-type epithelium
(Figure 3D), yet no mutation was found in squamous
epithelium of the mature cystic teratoma (data not
shown). Furthermore, no mutations were found in BRAF
(Figure 3B) or EGFR (Figure 3C) genes in either part.
The other patient was a 43-year-old perimenopausal fe-
male, gravida 2, para 1, presented in September 2012 for a
routine pelvic examination; an adnexal mass was found.
Her case was in highly similar to the first case but harbor-
ing a different KRAS mutation in codon 12 of the KRAS
gene (NM_004985.3):c. 34G > T, p. (Gly12Cys). We
summarized the relevant clinical and pathological findings
of all the previous reports on adenocarcinoma of the
gastrointestinal type arising from MCTs of the ovary
and presented in Table 1.
Conclusions
We present two cases with similarity of primary adeno-
carcinoma of the gastrointestinal type, harboring KRAS
oncogene mutation, likely arising in a mature cystic tera-
toma of the ovary. As far as we know, these two cases
are unique because currently there have been few report
on teratoma-associated adenocarcinoma carrying KRAS
oncogene mutation [1,4-8,21,22].
Malignant transformation of MCTs is a rare, often
asymptomatic event which most commonly occurs in
postmenopausal women. Also there have been plenty ofTable 1 Previous reports of adenocarcinoma of the gastrointe
Case Source Age Tumor marker
1 Ueda G et al. [4] 62 N.E.
2 Fishman A et al. [17] 38 CEA: 40 ng/ml CA 125: 80 U/ml CA153:
60 U/ml
3 Kushima M [18] 52 CA19-9: 109 U/ml SLX: 58.5 U/ml CA125:
36 U/ml CA72-4: 19 U/ml
4 Levine DA [19] 37 CEA: 11.2 ng/ml CA 125, AFP, HCG: WNR
5 Guney M [20] 38 CA1 25: 99.1 U/ml CA19-9 > 1000 U/ml
CEA: WNR
6 Min KJ [6] 77 CA125: 72 U/ml
7 Takai M [7] 49 CEA: 6.9 ng/ml CA 125: 20 U/ml CA19-9:
3.8 U/ml SCC: 1.1 ng/ml
8 Dov Hershkovitz [21] 13 CA-19-9:162 U/ml CEA: 5.5 ng/ml
CA-125: 268 U/ml AFP, HCG: WNR
9 Present case 51 CA19-9: 41.9 U/ml CEA, CA 125,
AFP: WNR
43 CA199 > 1200 U/ml
1: TAH: total abdominal hysterectomy, SO: salpingo-oophorectomy, OMT: omentectomy,
lymphadenectomy.
2: FAMT: 5-furuorouracil + endoxan +mitomycin-C + toyomycin, P + C: paclitaxel + ca
3: N.E.: not examined, N.D.: no description, WNR: within normal ranges.varying reports on that, the risk of malignancy is esti-
mated to be between 0.17 – 2% among all the transfor-
mations. As expected, any component of the MCTs
might undergo malignant transformation, but most of
the time (about 80%) squamous epithelium is the most
often prone to undergo malignant changes, which results
in the squamous carcinoma [3]. Some less common ma-
lignancies include thyroid carcinomas [23], adenocarcin-
omas [1,4-7], or, less commonly, carcinoid tumors [24],
mixed thyroid-carcinoid (struma carcinoid) [25].
The literature establishing adenocarcinoma of the
gastrointestinal type is much rarer. To our knowledge,
so far there have been only a few reports on it
[4,6,7,17-19,21,22,26]. Although Kajo K et al. reported a
case about mucinous carcinoma of non-intestinal type
arising in the ovarian MCT [5], yet most of the previously
described adenocarcinoma in MCTs showed characteris-
tics of intestinal differentiation with immunohistochemical
expression of CDX-2 and CK-20, and with negativity of
CK-7 [7,22]. In present study, the immunohistochemical
analysis showed positive staining in the CDX-2, CK-20
and villin, while the adenocarcinoma part was negative
for CK-7, ER and HER2. The patient also underwent
gastrointestinal endoscope to rule out the possibility of
metastasis. Therefore, the diagnosis of present cases is
adenocarcinoma of the intestinal type arising from a
MCT.
The pathogenesis of mucinous adenocarcinoma arising
from MCTs is somewhat different from that of colorec-
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6.4 × 4.8 ×
2.8
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15 × 12 × 11 Unilateral SO +
OMT + PLN + PAN
Ia none 40 month
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Ia none N.D.
17 × 14×2 TAH + BSO Ia none 12 month
6.7 × 5.7 TAH + BSO + OMT Ic(b) none 5 years
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Ia P + C 13 month
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APT: Appendectomy, PLN: pelvic lymphadenecomy, PAN: para aortic
rboplatin.
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MCT are the same as in colorectal adenocarcinoma, more
investigations are needed for further understanding patho-
genesis particularly using molecular genetic analysis, like
detection of mutation status. Although it has been claimed
that colorectal adenocarcinoma is genetically similar to an
intestinal-type adenocarcinoma in lung [20], so far there
have been few reports on genetic comparison between
colorectal adenocarcinoma and mucinous adenocarcin-
oma arising from MCTs. Reasons for the problem may be
due to the limited case number and difficulty in separating
the areas between the mucous components and adenocar-
cinoma part. Interestingly, recent studies on analysis of
microsatellite polymorphism in mucinous ovarian carcin-
omas and associated teratomas showed a clonal match be-
tween the samples, suggesting that a subset of mucinous
ovarian carcinoma actually arise from mature teratomas
[27]. Fujii K et al. also demonstrated that the origin of the
intestinal-type mucinous tumors might arise from mature
cystic teratomas by microdissection and analysis of micro-
satellite markers [28]. Related studies gave us a clue to iso-
late different teratoma components and explore molecular
genetic analysis.
It is difficult to make a diagnosis of malignant trans-
formation of a MCT preoperatively. The patient’s age, ex-
tremely enlarged mass in adnexal region by imaging and
elevated tumor maker might remind the possibility of ma-
lignancy. In preset study, both patients were perimeno-
pausal. Not only were the imaging results abnormal, but
also the tumor maker CA199 elevated. Yet, extensive
histological sampling was still crucial to reveal the carcin-
oma part, especially for local malignancy. In present cases,
mutation analysis of molecular alterations showed a KRAS
mutation in both the adenocarcinoma part and benign
intestinal-type epithelium of the cyst. KRAS mutations
were observed in 43% of ovarian carcinomas and in 30%
of colorectal carcinomas, which do not contribute to dif-
ferential diagnosis in mucinous neoplasms of the colon
and ovary [5]. Yet, mutation analysis might contribute to
predict the malignant transformation in MCTs in case of
under-diagnosis, especially for small lesion of malignancy.
Moreover, the absence of KRAS mutation in the mature
teratoma element in our samples suggests that this muta-
tion accompanies with the intestinal-type epithelium.
The prognosis of patients with malignant transform-
ation in MCTs is generally poor [29] and the majority of
women die within a year after diagnosis [1]. The top
affecting factor is tumor dissemination [30]. Thus, es-
tablishing an optimal therapeutic plan is important. So
far, the treatment of choice for these tumors is surgery
and there is little information on treatment outcomes
of patients receiving chemotherapy directed to trans-
formed histology given localized disease at presenta-
tion. Unfortunately, with tumors extending beyond theovary, prognosis seems to be very poor. Dechaphunkul A
et al. reported a case that a patient who achieved good re-
sponse from chemotherapy directed to transformed hist-
ology, which confirms the importance of chemotherapy
regimen used [31]. It brought us a new strategy of treat-
ment by targeting at transformed histology. KRAS status
is presently the only biomarker routinely used to select pa-
tients with colon cancer for EGFR inhibition-targeted
therapy, which is widely used to treat metastatic colorectal
cancer [32]. Thus we speculated if there was any chance
for anti-EGFR antibody therapies after failure of first-line
therapies, especially for metastasized patients. Further
conclusions on selecting anti-EGFR antibody therapies
need larger numbers of case studies and molecular genetic
analysis in the intestinal-type adenocarcinoma arising
from MCTs. Still, a risk and benefit discussion should be
had with the patient, keeping in mind her age, comorbidi-
ties, surgical, and pathological findings.
Our case represents two unique cases of single ovarian
MCT with malignant transformation to gastrolintestinal
adenocarcinoma carrying KRAS mutation.
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